Biotech · Public company · Irvine, CA, US
Eledon Pharmaceuticals, Inc.
Ticker ELDN · SEC CIK 0001404281
Track this companyFree. Adds Eledon Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials64 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline5
- AT-1501Phase 2 · Kidney Transplant RejectionClinicalTrials.gov · fetched Nov 12, 2026
- AT-1501Phase 2 · Prevention of Rejection in Kidney TransplantClinicalTrials.gov · fetched Nov 12, 2026
- AT-1501 IV InfusionPhase 2 · Brittle Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Isolated cadaveric islet cellsPhase 2 · Brittle Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- TacrolimusPhase 2 · Kidney Transplant RejectionClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Tolerance Through Mixed Chimerism (Sip-Tego)EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · started May 31, 2025ClinicalTrials.gov NCT06972069 · fetched Nov 12, 2026
- Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 4, 2024ClinicalTrials.gov NCT06305286 · fetched Nov 12, 2026
- Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant RecipientsPHASE2 · ENROLLING_BY_INVITATION · started Oct 25, 2023ClinicalTrials.gov NCT06126380 · fetched Nov 12, 2026
- Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney TransplantationPHASE2 · COMPLETED · started Aug 30, 2023ClinicalTrials.gov NCT05983770 · fetched Nov 12, 2026
- Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1DPHASE1_PHASE2 · WITHDRAWN · started Sep 30, 2022ClinicalTrials.gov NCT05480657 · fetched Nov 12, 2026
- Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney TransplantPHASE1_PHASE2 · RECRUITING · started Feb 18, 2022ClinicalTrials.gov NCT05027906 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 7, 2025 · fetched Nov 12, 2026